| Agenda - GVIRF 2023 - PRINTABLE | GVIRF Secretariat | 2023 | Presentation | English |
| GVIRF 2023 Poster Abstracts | GVIRF Secretariat | 2023 | Poster/infographic | English |
| GVIRF 2023 Welcome and Opening Remarks | Lee Hall | 2023 | Webinar | English |
| Keynote 1 - Vaccines in the Post-COVID Era: Can Policy and Practice Keep up with Science | Barney Graham | 2023 | Webinar | English |
| Keynote 2 - Future Pandemic R&D Preparedness in Korea and Translating Pandemic R&D Learnings into the Broader Global Health Agenda | Heechang Jang, NIH Korea; Jerome Kim, IVI | 2023 | Webinar | English |
| KN1 Vaccines in the post-COVID era: Can policy and practice keep up with science? | Barney Graham | 2023 | Presentation | English |
| KN2-1 Future Pandemic R&D Preparedness in Korea | Hee-Chang Jang | 2023 | Presentation | English |
| KN2-2 Translating pandemic R&D learnings into the broader global health agenda | Jerome Kim | 2023 | Presentation | English |
| P1 From GVAP to IA2030: roles of vaccine R&D to enable success | Lee Hall | 2023 | Webinar | English |
| P1-1 Overview of GVAP and IA2030 | Lee Hall | 2023 | Presentation | English |
| P1-2 Lessons Learned from the Global Vaccine Action Plan | Noni MacDonald | 2023 | Presentation | English |
| P1-3 Looking Ahead – Themes that will influence the R&D agenda | Helen Matzger | 2023 | Presentation | English |
| P1-4 IA2030 Strategic Priority 7: Research & Innovation. Overview and goals | Kwaku Poku Asante | 2023 | Presentation | English |
| P1-5 Partnering with regions and countries to identify priority pathogens for vaccines | Birgitte Giersing | 2023 | Presentation | English |
| P2 - Lessons from COVID-19 vaccines and future pandemic preparedness | Charlie Weller | 2023 | Webinar | English |
| P2-2 Research & innovation: Outbreaks preparedness & response | Ana Maria Henao Restrepo | 2023 | Presentation | English |
| P2-3 CEPI's Lessons Learnt from COVID-19 pandemic response and the 100 day mission for pandemic preparedness | Melanie Saville | 2023 | Presentation | English |
| P2-4 Regulatory Perspective: Brazil | Gustavo Santos | | Presentation | English |
| P2-5 Lessons learned from an industry R&D perspective | Tonya Villafana | 2023 | Presentation | English |
| P3 - Current status of R&D for HIV, TB, Malaria, and Universal Influenza vaccines (and reports from Workshops 1-3) | Annie Mo, Jerome Kim | 2023 | Webinar | English |
| P3-1 Introduction: Current status of vaccine R&D for HIV, Tb, Malaria, and Universal flu | Annie Mo | 2023 | Presentation | English |
| P3-3 Tuberculosis Vaccine R&D | Mark Hatherill | 2023 | Presentation | English |
| P3-4 HIV Vaccine Update | Shan Lu | 2023 | Presentation | English |
| P3-5 Current Status of Universal Influenza Vaccine Research and Development | Punnee Pitisuttithum | 2023 | Presentation | English |
| P4-1 The Full Value of Vaccines Assessment (FVVA) concept | Mark Jit | 2023 | Presentation | English |
| P4-2 Using the FVVA framework to estimate the potential health and economic impacts of novel TB vaccines in low- and middle-income countries | Richard White | 2023 | Presentation | English |
| P4-3 The Full Vacccine Accessment for Group A Streptococcus Vaccines | David Bloom | 2023 | Presentation | English |
| P4-4 A Pathway to Impact: Exploring the potential of measles rubella microarray patches to reach zero dose children and improve measles vaccine coverage through an initial Full Value Vaccine Assessment | Jean-Pierre Amorij | 2023 | Presentation | English |
| P5 - Innovating to find and reach Zero-Dose Children | Samir Sodha | 2023 | Webinar | English |
| P5-1 Introduction to Zero-Dose | Samir Sodha | 2023 | Presentation | English |
| P5-2 Mapping the distribution of zero-dose children and their characteristics in low- and middle-income countries | C. Edson Utazi | 2023 | Presentation | English |
| P5-3 Using mHealth Interventions to Improve Vaccination Coverage | Abdul Momin Kazi | 2023 | Presentation | English |
| P5-4 Strengthening Routine Immunization: Use of Reaching Every District - Quality Improvement (RED-QI) approach | Melkamu Ayalew | 2023 | Presentation | English |
| P6 - Vaccine technologies for equity | Philippe-Alexandre Gilbert | 2023 | Webinar | English |
| P6-2 The Vaccine Innovation Prioritisation Strategy (VIPS): driving innovations to improve vaccine delivery in low- and middle-income countries | Jean-Pierre Amorij | 2023 | Presentation | English |
| P6-3 A low footprint vaccine manufacturing platform for in-country, for-country production | Mathias Garny | 2023 | Presentation | English |
| P6-4 Single Injection Vaccines | Ana Jaklenec | 2023 | Presentation | English |
| P6-5 EuBiologics’s Vaccine Technologies for Equity | Rachel Park | 2023 | Presentation | English |
| P7 Optimizing vaccine regimens | Andrew Pollard, Kristen Earle | 2023 | Webinar | English |
| P7-1 GVIRF Plenary 7: Optimizing vaccine regimens | Kristen Earle | 2023 | Presentation | English |
| P7-2 Optimizing immunization schedules | Naor Bar-Zeev | 2023 | Presentation | English |
| P7-3 Impact on immunogenicity: Dose, Schedule and Platform | Andrew Pollard | 2023 | Presentation | English |
| P7-4 Optimizing vaccine regimens – HPV Vaccines | Deborah Watson-Jones | 2023 | Presentation | English |
| P7-5 Timing of South Africa's PCV and Measles infant doses: considerations on the adoption of a vaccine schedule | Rudzani Muloiwa | 2023 | Presentation | English |
| P8 - Reflections and closing remarks: Progress and the path forward | Noni MacDonald, Dalhousie U. | 2023 | Webinar | English |
| W1 - Immunological and Vaccine Considerations for Special Populations: women of reproductive age and pregnancy, people living with HIV, and older adults | Carolyn Deal, Ruth Karron | 2023 | Webinar | English |
| W1-2 Vaccines for special populations: Immunological considerations | Arnaud Didierlaurent | 2023 | Presentation | English |
| W1-3 Group B Streptococcus Vaccination in Pregnant Women | Anna Seale | 2023 | Presentation | English |
| W1-4 TB Vaccine Roadmap for People Living with HIV | Mindy Miner | 2023 | Presentation | English |
| W1-5 COVID 19 vaccine effectiveness in the elderly population | Tarun Saluja | 2023 | Presentation | English |
